Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342926 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT01342926 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 191 participants.
The verdict
NCT01342926, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.
Interventions
- DRUG Placebo
- DRUG GSK933776
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2016-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01342926
The ClinicalTrials.gov registry entry for NCT01342926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01342926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01342926 about?
NCT01342926 is a clinical study titled "Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.
What is the current status of trial NCT01342926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2011-06-01. Estimated completion is 2016-04-01.
What interventions are being tested in trial NCT01342926?
The interventions under investigation include: Placebo (DRUG), GSK933776 (DRUG).
Who is sponsoring clinical trial NCT01342926?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.